Amgen director receives 665-share RSU grant

Drake Michael V reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Drake Michael V reported acquisition or exercise transactions in this Form 4 filing.

Amgen Inc. director Michael V. Drake received 665 shares of common stock as a grant of Restricted Stock Units (RSUs). The RSUs were awarded under Amgen’s 2009 Director Incentive Program and vested immediately, paying out in common shares on a one-to-one basis. Following this award, Drake directly holds about 5,774.2869 Amgen shares, including 339 dividend equivalents credited to his unvested RSUs.

Insider Trade Summary

Grant/Award: 665 shares

Grant/Award 1 txn

Insider Drake Michael V

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	665	$0.00	$0.00

Holdings After Transaction: Common Stock — 5,774.2869 shares (Direct)

Footnotes (2)

F1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.
F2. These shares include 339 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

RSU shares granted: 665 shares Price per share: $0.0000 per share Total shares after transaction: 5,774.2869 shares +2 more

5 metrics

RSU shares granted 665 shares Common Stock grant/award on May 19, 2026

Price per share $0.0000 per share Reported transaction price for RSU grant

Total shares after transaction 5,774.2869 shares Direct Amgen holdings following RSU grant

Dividend equivalents included 339 DEs Credited to unvested RSUs under equity incentive plan

Transaction code A Grant, award, or other acquisition of common stock

Key Terms

Restricted Stock Units (RSUs), Amgen Inc. 2009 Director Incentive Program, Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, Dividend Equivalents (DEs), +1 more

5 terms

Restricted Stock Units (RSUs) financial

"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program..."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Amgen Inc. 2009 Director Incentive Program financial

"RSUs were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended..."

Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan financial

"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan..."

Dividend Equivalents (DEs) financial

"These shares include 339 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan..."

qualifying dividend reinvestment plan financial

"339 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amgen (AMGN) director Michael V. Drake report in this Form 4?

Michael V. Drake reported receiving 665 shares of Amgen common stock as a grant of Restricted Stock Units. These RSUs vested immediately and were paid in shares on a one-to-one basis under Amgen’s director incentive and equity incentive plans.

Is Michael V. Drake’s Amgen Form 4 transaction a market purchase or sale?

The Form 4 shows a grant/award acquisition, not an open-market trade. Drake received 665 shares of Amgen common stock from vested Restricted Stock Units as part of director compensation, with no cash price per share reported in the transaction.

How many Amgen (AMGN) shares does Michael V. Drake hold after this RSU grant?

After the grant, Michael V. Drake directly holds 5,774.2869 shares of Amgen common stock. This total includes 339 dividend equivalents credited to his unvested RSUs, which will be paid out in shares according to the applicable vesting schedules.

What are the key terms of the RSUs reported by Michael V. Drake at Amgen?

The Restricted Stock Units were granted under Amgen’s 2009 Director Incentive Program and Second Amended and Restated 2009 Equity Incentive Plan. They vested immediately and pay out in Amgen common stock on a one-to-one basis, with optional deferral according to an elected schedule.

What are dividend equivalents (DEs) mentioned in Michael V. Drake’s Amgen filing?

Dividend equivalents are credits linked to unvested RSUs under Amgen’s equity plan. Drake’s holdings include 339 DEs that will be paid in Amgen common shares on a one-to-one basis when the related RSUs vest, plus a cash payment for any remaining fractional share amount.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/21/2026 - 06:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drake Michael V

(Last)

(First)

(Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS

CALIFORNIA

91320

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/19/2026		A		665	A	$0	5,774.2869⁽¹⁾⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

2. These shares include 339 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Michael V. Drake	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR